Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385953 | 0.77 | ADAMTS4 (0.45) | CYSLTR2CYSLTR1KDM4EPSMB5ALDH1A1 | |
| SCHEMBL6566282 | 0.75 | ALDH1A1 (0.56) | KEAP1SMN1; SMN2LMNAKDM4ECA12 | |
| SCHEMBL24943587 | 0.74 | HDAC1 (0.55) | SMN1; SMN2CYSLTR2CYSLTR1KDM4EKDM1A | |
| SCHEMBL1873887 | 0.72 | PRMT1 (0.77) | SMN1; SMN2LMNAALDH1A1MEN1POLB | |
| SCHEMBL15578063 | 0.72 | HDAC1 (0.61) | CYSLTR2CYSLTR1KDM1AMAOAMAOB | |
| SCHEMBL1868959 | 0.72 | CYP1A2 (0.57) | KEAP1SMN1; SMN2LMNAKDM4EKDM1A | |
| SCHEMBL4371435 | 0.71 | MAOA (0.51) | SMN1; SMN2CYSLTR2CYSLTR1KDM4EKDM1A | |
| SCHEMBL2924050 | 0.71 | NCF1 (0.53) | SMN1; SMN2LMNACYSLTR2CYSLTR1KDM4E | |
| SCHEMBL5547093 | 0.71 | HDAC1 (0.55) | SMN1; SMN2CYSLTR2CYSLTR1KDM4EKDM1A | |
| SCHEMBL28879846 | 0.71 | KDM1A (0.50) | SMN1; SMN2CYSLTR2CYSLTR1KDM4EKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | NEITZEL MARTIN | 2011-09-01 | — | — | US | disclosed |
| US-7939657-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | KEAP1 168/4885SMN1; SMN2 3044/4885LMNA 2773/4885 |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | KEAP1 244/4885SMN1; SMN2 259/4885LMNA 3012/4885 |
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | KEAP1 244/4885SMN1; SMN2 259/4885LMNA 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.